Citius Pharmaceuticals Completes Merger of Oncology Subsidiary With Blank Check Firm TenX Keane

MT Newswires Live

2024/08/13

Citius Pharmaceuticals (CTXR) said late Monday it has completed the pending merger of its oncology subsidiary and blank check firm TenX Keane Acquisition (TENK).

The combined company has been renamed Citius Oncology, with its stock expected to debut on Nasdaq on Aug. 13 under the ticker, "CTOR."

Pursuant to the deal, Citius Pharmaceuticals owns about 90% equity of Citius Oncology.

Price: 0.6798, Change: -0.01, Percent Change: -1.65

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2459947907"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2459947907\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2459947907?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-08-13 15:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2459947907","market":"sh","top_or_hot":-1,"title":"Citius Pharmaceuticals Completes Merger of Oncology Subsidiary With Blank Check Firm TenX Keane","media":"MT Newswires Live","content":"<html><body><p> Citius Pharmaceuticals (CTXR) said late Monday it has completed the pending merger of its oncology subsidiary and blank check firm <a href=\"https://laohu8.com/S/TENKU\">TenX Keane Acquisition</a> (TENK).</p><p>The combined company has been renamed Citius Oncology, with its stock expected to debut on Nasdaq on Aug. 13 under the ticker, \"CTOR.\"</p><p>Pursuant to the deal, Citius Pharmaceuticals owns about 90% equity of Citius Oncology.</p><p>Price: 0.6798, Change: -0.01, Percent Change: -1.65</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Citius Pharmaceuticals Completes Merger of Oncology Subsidiary With Blank Check Firm TenX Keane</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCitius Pharmaceuticals Completes Merger of Oncology Subsidiary With Blank Check Firm TenX Keane\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2024-08-13 15:41</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Citius Pharmaceuticals (CTXR) said late Monday it has completed the pending merger of its oncology subsidiary and blank check firm <a href=\"https://laohu8.com/S/TENKU\">TenX Keane Acquisition</a> (TENK).</p><p>The combined company has been renamed Citius Oncology, with its stock expected to debut on Nasdaq on Aug. 13 under the ticker, \"CTOR.\"</p><p>Pursuant to the deal, Citius Pharmaceuticals owns about 90% equity of Citius Oncology.</p><p>Price: 0.6798, Change: -0.01, Percent Change: -1.65</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CTXR","symbol_name":"Citius Pharmaceuticals, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2459947907","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2459947907","pubTimestamp":1723534901,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Citius Pharmaceuticals  said late Monday it has completed the pending merger of its oncology subsidiary and blank check firm TenX Keane Acquisition .The combined company has been renamed Citius Oncology, with its stock expected to debut on Nasdaq on Aug. 13 under the ticker, \"CTOR.\"Pursuant to the deal, Citius Pharmaceuticals owns about 90% equity of Citius Oncology.Price: 0.6798, Change: -0.01, Percent Change: -1.65","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CTXR":"Citius Pharmaceuticals, Inc.","BK4007":"制药"},"translate_title":"Citius Pharmaceuticals完成肿瘤子公司与空白支票公司TenX Keane的合并","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TENK":0.9,"CTXR":0.9},"content_text":"Citius Pharmaceuticals (CTXR) said late Monday it has completed the pending merger of its oncology subsidiary and blank check firm TenX Keane Acquisition (TENK).The combined company has been renamed Citius Oncology, with its stock expected to debut on Nasdaq on Aug. 13 under the ticker, \"CTOR.\"Pursuant to the deal, Citius Pharmaceuticals owns about 90% equity of Citius Oncology.Price: 0.6798, Change: -0.01, Percent Change: -1.65","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}